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EFFECTS OF EDUCATIONAL INTERVENTIONS FOR SELF-MANAGEMENT OF
ASTHMA IN CHILDREN AND ADOLESCENTS: AN UPDATED SYSTEMATIC
LITERATURE REVIEW AND META-ANALYSIS
Nguyen HP1, Wong S1, Schrauben L2, Clark NM2, Grum CM2, Guevara JP3, Wolf FM1
1University of Washington, Seattle, WA, USA, 2University of Michigan, Ann Arbor, MI, USA,
3University of Pennsylvania School of Medicine, Philadelphia, PA, USA
OBJECTIVES: To update a previously published systematic literature review and
meta-analysis investigating the effectiveness of asthma self-management educa-
tion programs on health outcomes in children. METHODS: The updated search is
through June 2010 and included published meta-analysis or journals from MEDLINE,
EMBASE, and the Cochrane Central Register of Controlled Trials. All available Eng-
lish abstracts were reviewed and the full text was consulted as necessary to clarify
eligibility status. Eligible studies were randomized controlled trials or controlled
clinical trials that evaluated outcomes in children ages 2-18 years with a diagnosis
of asthma. Data were extracted on the study population, intervention types, sam-
ple size, sample size calculations, loss to follow-up, outcomes, andmethodological
quality of the studies. Datawere pooled using both fixed effects and randomeffects
models. Effect estimates were plotted in forest plots and heterogeneity was as-
sessed visually and statistically using the I2 statistic. All data were analyzed using
RevMan software. RESULTS: Preliminary results with the addition of several recent
studies suggested that educational programs for the self-management of asthma
in children were associated with modest to moderate improvement in several
outcomemeasures, such as themean number of emergency department visits (n
17 studies; SMD: 0.67; 95% CIs: 1.23, 0.11; I2  97%) and mean number of
hospitalizations (n 11 studies; SMD: 0.50; 95% CIs: 0.70, 0.29; I2  62%). The
results for random effects models were similar to fixed effects models.
CONCLUSIONS: Incorporating educational programs for self-management into the
routine care of children and adolescents with asthma may significantly improve
outcomes. This update will improve the power of small or inconclusive studies,
allowing for analysis of subgroup effects and the comparative effectiveness of
alternative strategies. Results are preliminary and a full update of the meta-anal-
ysis is forthcoming.
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PATIENT SELF-MANAGEMENT OF ASTHMA: A STUDY IN AN EMERGENCY
ROOM OF A CHEST HOSPITAL IN DELHI, INDIA
Kotwani A, Shendge S, Vijayan V
V. P. Chest Institute, University of Delhi, Delhi, India
OBJECTIVES: Asthma, a chronic disease requires lifelong adherence to medication
and optimal self-management. Studies indicate that worldwide self-management
of asthma is poor and evidence-based suitable interventions are needed for asthma
control. The present study was conducted to investigate the pattern of self-man-
agement in asthmatic patients in Delhi, India. METHODS: Adult asthma patients
(n200) visiting emergency room (December 2008-December 2009) of a tertiary care
referral chest hospital for asthma exacerbation completed self-report question-
naire on self-management of asthma after stabilization.Written informed consent
from patients and ethical clearance from institute was obtained. Questionnaire
contained 51 questions having six domains: Socio-demographic profile, clinical
profile, morbidity and activities of living, access to care, asthma attack prevention
and emergency actions. RESULTS: Study population had 64% female, 51.5% be-
tween 30-40 year and 10% were illiterate. Patients were enrolled as asthma out-
patients in the study hospital for 5.44.4 years. All patients except one were pre-
scribed corticosteroidbeta2 agonist inhalers. Patients visiting ER and having
unscheduled visit to doctor at least twice in the previous 12monthswere 86.5% and
91% respectively. Patients were classified according to the disease severity as hav-
ing intermittent (17%) or persistent (83%) asthma. Majority of patients visited the
study hospital for usual source of treatment and in case of exacerbation. Not all
patients had meter dose inhalers at home. Only 2% patients were prescribed peak
flow meter and one patient reported using it regularly and keeping diary. No sta-
tistical difference was found in pattern of self-management by patients having
persistent or intermittent asthma. Except one, no patient had any written action
plan for treatment or for emergency. CONCLUSIONS: Findings revealed poor self-
management of asthma and lack of communication between doctor and patient.
Immediate action is needed to impart knowledge of self-management and written
action plan for asthma patients by physicians.
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PHARMACY QUALITY INDICATORS USING MISSISSIPPI MEDICAID: TESTING
PQA-ENDORSED STARTER SET MEASURES AND 2010 TEST MEASURES
Thumula V, Banahan BFI, Bentley JP, West-Strum D
University of Mississippi, University, MS, USA
OBJECTIVES: (1) To understand how multiple pharmacy use affects the ability to
compute pharmacy quality indicators (PQIs). (2) To determine the number of phar-
macies that have sufficient Medicaid claims to compute PQIs. METHODS: An ob-
servational cohort study of Mississippi Medicaid data for 2002 and 2004 was con-
ducted. Patients with medication claims related to each measure, continuously
enrolled, and without institutional care during the measurement year were eligi-
ble. The PQIs in the Pharmacy Quality Alliance ‘(PQA)-endorsed starter set’ were
computed at the patient level and aggregated to the pharmacy level by attributing
each beneficiary to the pharmacy that dispensed the most (and alternative criteria
of 50% and 75%) of their drugs for themeasure. Pharmacies with at least 30 eligible
members per measure were considered reliable. Additionally, the 2010 PQA test
measures (adherence to anticonvulsants and antiretrovirals, statin use with CAD,
asthma management) were evaluated. RESULTS: The majority of patients (three-
fourths) obtained over 90% of their diabetes and cardiovascular medications from
one pharmacy. Around 85% and 97% of the patients obtained over 75% and over
50% of theirmedications from a single pharmacy respectively. Only 55% of patients
received antiretroviral medications from a single pharmacy. For the adherence/
persistence measures, 6.3% to 65.3% of the pharmacies had reliable measures in
2002. 78.2% of the pharmacies could be included for the high-risk medications in
elderly measure and 2.7% of the pharmacies qualified for the CAD measure. Less
than 10 pharmacies qualified for the asthmamanagement and antiretroviral med-
ication adherence measures. A similar pattern was observed in 2004.
CONCLUSIONS: The attribution strategy proposed by PQA can bemademore strin-
gent without severely limiting the number of pharmacies with measures. Using a
pharmacy attribution criteria of 50% or 75% of fills from the same pharmacywill
result in more reliable PQI metrics.
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HOSPITALIZATIONS, MEDICAL MANAGEMENT AND SWITCH THERAPY
PATTERNS IN THE COPD MEDICARE POPULATION
Ejzykowicz F1, Hay J1, Sarocco P2, Karafilidis J2, Walsh J2
1University of Southern California, Los Angeles, CA, USA, 2Sunovion Pharmaceuticals Inc.,
Marlborough, MA, USA
OBJECTIVES: To evaluate whether hospitalization rates differ between COPD pa-
tients who switched therapy and/or have bettermedical management in theMedi-
care population. METHODS: This is a cross-sectional retrospective study of COPD
Medicare patients between January 2006 and December 2008. Eligible patients had
at least one claim for COPD in 2006 as 1st diagnosis and were also continuously
eligible for parts A, B and D during the study period. Patients enrolled in Medicare
Advantage, diagnosed with asthma and younger than 65 years old were excluded.
Therapy switch was defined as patient switching all drugs taken in the previous
year. Probability of hospitalization was estimated using a logit model with regres-
sors of age, gender, race, previous hospitalization, previous therapy, previous
COPD test, physician visits and comorbidities. RESULTS: A total of 44,933 patients
were included in the study. The average age was 77.8 years old. A majority of the
patients were female (64.1%), and white (89.8%). Congestive heart failure, diabetes
and hyperlipidemia were the most common comorbidities. The most frequently
prescribed therapy was oxygen (around 30%), followed by Short-Acting Beta Ago-
nists (14%). Patientswho received greater COPDmedicalmanagement as defined as
COPD therapy (including higher OCS use), number spirometry tests and physician
visits for COPDwere associatedwith decreased likelihood of hospitalization in 2008
(p-value  0.05). Moreover, therapy discontinuation, new therapy starters, weight
loss, hyperlipidemia, liver disease, coagulapathy and renal failure were associated
with higher COPD hospitalization risk while depression, congestive heart failure
with lower hospitalization risk (p-values  0.05). Also, in this population around
21% visited a specialist physician, 14% had ER visit and 20% were hospitalized for
COPD in 06, 07, 08. CONCLUSIONS: The findings suggest that patients maintaining
the same therapy across years and patients with greater COPDmedical management
are less likely to be hospitalized compared to patients with worse disease control.
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THE PRICE NEGOTIATION ON PHARMACEUTICALS AFTER THE INTRODUCTION
OF POSITIVE LIST SYSTEM IN SOUTH KOREA
Yoon SY, Lee EK
Sookmyung Women’s University, Seoul, South Korea
OBJECTIVES: In Korea, the price of new drug has been decided through price ne-
gotiation after evaluation for reimbursement in decision process since 2007. The
price of new drug was negotiated considering price of reference drugs, budget
impact analysis, substitution rate, etc. This study attempted to analyze states of
new drugs’ listing and identify influential factor in reimbursement and pricing
negotiation, and to analyze satisfaction of pharmaceutical companies concerned
on price negotiation. METHODS: Data on reimbursement for 3 years (2007.01.01-
2009.12.31) were obtained from the agency’s website posting results for reimburse-
ment determination, and Korean Ministry of Health and Welfare Affairs’ drug no-
tification on the results of price negotiation. The questionnaire consisting of
negotiation guideline (article 10, 11) and satisfaction was made and used to collect
responses of pharmaceutical companies’ working group. The e-mail for the survey
was sent out to 31 companies, survey response rate was 71%. RESULTS: Cost-
effectiveness (84.5%) was affecting factor of reimbursement in decision process.
The lead time of reimbursement and pricing was around 12.8months. The listing
price was determined as average 67% compared to application price, application
price was cut by approximately 20% in decision-making of reimbursement, after
that, that price was cut by approximately 17% in price negotiation process. In
negotiation process, the price of reference drugs had great influence on results of
negotiation. Mainly the lowest price in therapeutic area was referenced in negoti-
ation process. Negative perceptions on process of pricing negotiation were found
especially predictability of price and appreciating its value, and the needs for de-
tailed guideline have been mentioned. CONCLUSIONS: The satisfaction of negoti-
ation processwas very negative, the reasonwas that Positive list systemmade new
drugs’ listingmore difficult and lengthened the lead time of listing. To enhance the
negotiation process, it is necessary to develop the detailed guideline on process of
price negotiation.
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OBJECTIVES: To determine the effect of enrollment in a prescription drug plan on
use of controller medications in patients with persistent asthma. METHODS: The
study used a retrospective, cross sectional research design. The data source uti-
lized was the 2008 Medical Expenditure Panel Survey (MEPS), a nationally repre-
sentative sample of the non-institutionalized, civilian U.S. population. Analysis
was restricted to asthma patients who reported use of more than 3 canisters of
rescue inhalers in a three-month period. Controller medication use was self-re-
ported byMEPS respondants. Descriptive statisticswas used to describe the sample
and their controller medication use. A logistic regressionmodel was used to assess
the effect of prescription drug coverage based on the type of prescription drug plan
on the controller medication use while adjusting for age, gender, race, ethnicity,
income and perceived health status. All analyses were carried out using SASv.9.1.
RESULTS: Forty-two percent of respondents had prescription drug coverage while
67% reported use of controller medications. In the regression model, controller
medication use was found to be similar amongst patients with prescription drug
coverage and patients without coverage (68%, 66%, respectively). Patients with
prescription drug coverage were less likely to use controller medications than
those who did not have coverage, although this effect was not significant (OR 
0.53,CI:0.28-1.01). Patients with Medicare (OR 4.35, CI:1.61-11.75), Medicaid (OR
5.44, CI:2.23-13.24) or Veterans Affairs (OR  12.82, CI:3.21-51.16) prescription cov-
erageweremore likely to use controllermedicationswhen comparedwith patients
in other types of plans. Both pediatric patients (OR  5.51, CI:1.27-23.88) and pa-
tients with excellent perceived health status (OR 5.10, CI:2.04-12.76) had a higher
likelihood of using controller medications. CONCLUSIONS: Enrollment in a pre-
scription drug plan did not show a significant impact on use of controller medica-
tions. However, enrollment in Medicare, Medicaid or Veterans Affairs prescription
plans increased likelihood of controller medication use in this patient cohort.
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EFFECT OF BIOMASS SMOKE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE
IN RURAL LOCALITIES OF COLOMBIA
Alvis N1, Paternina A1, Montes J1, De la Hoz F2
1Universidad de Cartagena, Cartagena de Indias, Bolívar, Colombia, 2Universidad Nacional de
Colombia, Bogota, D.C., Colombia
OBJECTIVES: The exposure to biofuel smoke is a risk factor for Chronic Obstructive
Pulmonary Disease –COPD- while using natural gas may be protective against it.
There is few evidence from Latin America on the relationship between use of
different types of fuels to cook and respiratory diseases. The present report is
aimed to assess differences in the prevalence of abnormalities to respiratory func-
tions between populations who used biomass fuel to cook against those using
cleaner sources of energy such as natural gas.METHODS: A cross-sectional popu-
lation based study was designed to evaluate the respiratory function, through spi-
rometry, in subjects cooking with biomass or natural gas. All patients were evalu-
ated by a general physician and a pulmonologist. We compared the prevalence of
spirometry abnormalities on those cooking with natural gas versus those cooking
with biomass fuel. A multivariable logistic regression was used to adjust differ-
ences by potential confounding factors. RESULTS: Overall 203 persons were stud-
ied. After adjusting by potential confounders there were a significant increase in
the prevalence of severe obstructive pattern (OR 5.50; 95% CI 1.17-25.79) in subjects
who cookwith biomass comparedwith natural gas users. Values of Forced Expired
Volume in one second (FEV1) and forced vital capacity (FVC) were lower among
those cooking with biomass. The differences in prevalence of respiratory mor-
bidity and symptoms were not statistically significant between both groups.
CONCLUSIONS: These findings suggest that replacing biomass fuel by natural gas
may be an important public health intervention in Colombia because it can reduce
the prevalence of abnormal patterns of pulmonary function.
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TRENDS IN ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS
FOR ADULTS IN THE UNITED STATES WITH NASOPHARYNGITIS, UPPER
RESPIRATORY TRACT INFECTIONS AND BRONCHITIS FROM 2006 TO 2008
Agrawal R, Shah J, Chopra P, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: The 2006 guidelines of the American Academy of Family Physicians
recommends to avoid prescribing of antibiotics to patients diagnosed with naso-
pharyngitis, acute upper respiratory tract infections (ARTI) or acute bronchitis.
Inappropriate prescribing of antibiotics to patients can lead to a rise in antibiotic-
resistant bacteria and subsequently increase the economic burden. The purpose of
this study was to determine the trends in the antibiotic prescribing rates for adults
diagnosed with nasopharyngitis, acute bronchitis or ARTIs in ambulatory care set-
tings in the United States after the 2006 guidelines. METHODS: This was a retro-
spective, cross-sectional analysis of the representative national survey of office
visits from theNational AmbulatoryMedical Care Survey for the years 2006 to 2008.
Adults18 years of age with a diagnosis of nasopharyngitis, ARTIs, or acute bron-
chitis were identified using International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes. Inappropriate antibiotic prescribing rates for the
three conditions were calculated separately and collectively. Descriptive analysis
was conducted to determine the utilization patterns by patient and physician char-
acteristics. Logistic regression was carried out to determine the trends in the anti-
biotic utilization. RESULTS: Analysis of multiyear data showed no statistically sig-
nificant trend (p-value  0.4622) in the antibiotic prescribing rates from 2006 to
2008. Approximately, 45.26 million office visits annually resulted in a primary di-
agnosis of nasopharyngitis, acuteURI, or acute bronchitis; of these visits, 1.5%, 44%,
and 61%, respectively, resulted in the prescribing of an antibiotic. Overall 47.26 % of
the study population was prescribed antibiotics. CONCLUSIONS: Antibiotic pre-
scription rate did not change significantly from 2006 to 2008. Antibiotics were pre-
scribed inappropriately in 47% of the adults diagnosedwith nasopharyngitis, ARTI,
or acute bronchitis. Concerted efforts are needed to improve antibiotic prescribing
practices for these conditions.
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A REAL-WORLD EVALUATION OF BETA AGONIST USE DURING
HOSPITALIZATIONS FOR COPD
Robinson SB1, Sarocco P2, Karafilidis J2, Walsh J2, Johnson BH1, Ernst FR1
1Premier Health Alliance, Charlotte, NC, USA, 2Sunovion Pharmaceuticals Inc., Marlborough,
MA, USA
OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health issue and is a leading cause ofmorbidity andmortality in the United States1.
High frequency of exacerbations can lead to the further decline in lung function in
patients with moderate to severe COPD2. The objectives of this study was to gain a
better understanding of short-acting and long-acting beta-agonist use (SABA and
LABA, respectively) in the inpatient setting and describe beta-agonist effects on
total cost and length of stay (LOS).METHODS:Data from the Premier Perspective™
Database, a US national representative hospital database, was used to identify the
study population, which included adults 40 and olderwith an inpatient visit having
a principal discharge diagnosis code of COPD (ICD-9-CM 491.xx, 492.xx, 496) be-
tween January 1, 2006 and March 31, 2010. RESULTS: There were 165,055 individ-
uals with a primary diagnosis code during an inpatient visit. The mean age for
SABA only users was 68.9 years and 67.7 years for LABA only users (p0.0001). The
majority of the patients were female (56.9% SABA only, 56.9% LABA only, p 
0.9988) and white (72.3% SABA only, 66.4% LABA only, p 0.0001). The unadjusted
mean total cost for LABAuserswas $5,727 compared to $7,084 for SABA (p0.0001).
LOSwas not different between LABA and SABAusers:mean 5.5 and 6.7 (p 0.4786).
Inpatientmortality for both beta-agonist user groupswas below two percent (1.50%
SABA versus 0.34% LABA, p  0.0001). CONCLUSIONS: Descriptive analyses indi-
cate there are some differences among individuals with COPD using only LABA use
compared to SABA only use during an inpatient visit. Modeling outcomes adjusting
for potential differences such as demographics and concomitant drug use will be
performed to further describe this population.
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CONCOMITANT ASTHMA MEDICATION USE IN PATIENTS USING
OMALIZUMAB: RESULTS FROM THREE LARGE INSURANCE CLAIMS DATABASES
Lafeuille MH1, Duh MS2, Zhang J3, Wertz D4, Gu T4, Tang J2, Lefebvre P1
1Groupe d’analyse, Ltée, Montreal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA,
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4HealthCore, Inc., Wilmington,
DE, USA
OBJECTIVES: This study describes concomitant asthmamedication use in patients
treated with omalizumab (Xolair®), a monoclonal antibody indicated for moderate
to severe persistent allergic asthma. METHODS: An analysis of health insurance
claims from three large databases was conducted: MarketScan (1996-2009), Medic-
aid (1997-2009), and Wellpoint (2002-2010). Patients 12 years old newly initiated
on omalizumab with 12months of continuous insurance coverage prior to the first
omalizumab dispensing (baseline period) and 2 asthma claims were included.
Concomitant asthmamedication usewas summarized in eightmedication classes:
ICS, LABA, leukotriene modifiers, mast cell stabilizers, anticholinergics, SABA,
methylxanthines, and oral corticosteroids, according to the 2007 National Asthma
Education and Prevention Program guidelines for managing asthma. RESULTS: A
total 6,038 patients were identified (Medicaid: 731; MarketScan: 3,521; Wellpoint:
1,786). Mean age (SD) was 38.8 (12.6), 44.6 (14.0), and 47.3 (15.6), and males repre-
sented 31%, 36%, and 39% in Medicaid, MarketScan, andWellpoint, respectively. A
high proportion of new omalizumab users have had an asthma-related ER visit
(Medicaid: 34%; MarketScan: 17%; Wellpoint: 16%) or hospitalization (Medicaid:
36%; MarketScan: 14%; Wellpoint: 21%) prior to initiating omalizumab. The major-
ity of patients (Medicaid: 96%; MarketScan: 89%; Wellpoint: 86%) received three
concomitant asthma medication classes or more during the baseline period. Con-
comitant ICS use was observed in 95%, 89%, and 86% of Medicaid, MarketScan, and
Wellpoint patients, respectively. Only 1% of omalizumab users in Medicaid and 3%
in MarketScan and Wellpoint received no other asthma medication prior to initi-
ating omalizumab. CONCLUSIONS: Based on this large observational study using
health insurance claims from three databases, a minority (1-3%) of omalizumab
users receive monotherapy treatment for asthma.
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REGRESSION VERSUS PROPENSITY MATCHING AS OUTCOME ANALYSIS
ADJUSTMENT METHODS: EXAMPLE USING COPD INITIAL THERAPIES
Roberts M1, Dalal AA2
1LCF Research, Albuquerque, NM, USA, 2GlaxoSmithKline, Durham, NC, USA
OBJECTIVES: Compare retrospective initial maintenance treatment (IMT) analyses
results from propensity matched (PM) comparisons to multiple regression (MR)
results (adjusted for treatment, demographics and pre-initiation comorbidities and
utilization). TheMRand PMmethods are twowidely usedmethods in observational
comparative outcome studies of pharmaceutical treatments to adjust for baseline
differences in non-randomized treatment populations, but research on the extent
to which study findingsmay differ between themethods is sparse.METHODS:One
year post-initiation cost differences and utilization outcomes (odds ratios (OR)/
incidence rate ratios (IRR) for emergency department visit (ED), hospitalization, or
combination of either ED or hospitalization) for subjects diagnosed with chronic
obstructive pulmonary disease (COPD) were reviewed using data (January 2004
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